Selvita S.A.
Selvita S.A. operates as a contract research organization worldwide. The company offers drug discovery services in the areas of AI-driven drug discovery, antibody drug discovery, structural biology, recombinant protein production, assay development and screening, computer-aided drug design, medicinal and synthetic chemistry, scale-up, ADME/DMPK, in vitro and In Vivo pharmacology, translational re… Read more
Selvita S.A. (SLV) - Total Liabilities
Latest total liabilities as of September 2025: zł294.51 Million PLN
Based on the latest financial reports, Selvita S.A. (SLV) has total liabilities worth zł294.51 Million PLN as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Selvita S.A. - Total Liabilities Trend (2015–2024)
This chart illustrates how Selvita S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Selvita S.A. Competitors by Total Liabilities
The table below lists competitors of Selvita S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SpareBank 1 Nord-Norge
PINK:SPXXF
|
USA | $12.51 Billion |
|
Zhejiang Yaguang Technology Co. Ltd. A
SHG:603282
|
China | CN¥1.25 Billion |
|
Responsive Industries Limited
NSE:RESPONIND
|
India | ₹3.88 Billion |
|
Shandong Teamgene Technology Co. Ltd. A
SHG:603151
|
China | CN¥1.48 Billion |
|
Vef AB
ST:VEFAB
|
Sweden | Skr29.87 Million |
|
Shanghai Lianming Machinery Co Ltd
SHG:603006
|
China | CN¥482.82 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Selvita S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Selvita S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Selvita S.A. (2015–2024)
The table below shows the annual total liabilities of Selvita S.A. from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł320.21 Million | +3.57% |
| 2023-12-31 | zł309.19 Million | -0.82% |
| 2022-12-31 | zł311.75 Million | +19.43% |
| 2021-12-31 | zł261.04 Million | +294.70% |
| 2020-12-31 | zł66.14 Million | +52.99% |
| 2019-12-31 | zł43.23 Million | +84.79% |
| 2018-12-31 | zł23.39 Million | +120.74% |
| 2017-12-31 | zł10.60 Million | -68.28% |
| 2016-12-31 | zł33.41 Million | +81.95% |
| 2015-12-31 | zł18.36 Million | -- |